Pluvicto prostate cancer treatment protocols vary globally

An international survey of treatment centers has revealed significant differences in several aspects of Lu-177 PSMA-617 prostate cancer therapy, including patient imaging protocols, according to a study published January 18 in the Journal of Nuclear Medicine.Aligning these differences could improve patient outcomes, noted lead author Andrea Farolfi, MD, of the University of California, Los Angeles, and colleagues.“Standardization or harmonization of protocols and dedicated training are desirable in anticipation of increasing numbers of patients and theranostic centers,” the group wrote.Pluvicto was approved by the U.S. Food and Drug Administration (FDA) in March 2022 for adults with prostate specific membrane antigen (PSMA)-positive metastatic cancer who have not responded to standard treatments. While Pluvicto has been swiftly adopted into international prostate cancer management guidelines, identifying potential operational differences and similarities in how it is delivered can improve consistency of care, the authors noted.To that end, the researchers sent a questionnaire comprising 62 items to 211 Pluvicto treatment centers globally in June 2022. They received 95 (45%) responses, with participants asked to provide answers about how patients are imaged and treated.Most participating centers were in Europe (51%), followed by the U.S. (22%) and Asia (22%), the group wrote. During the 12 months before the study, a total of 5,906 patients received Pluvicto therapy at th...

Source: AuntMinnie.com Headlines - January 23, 2024 Category: Radiology Authors: Will Morton Tags: Subspecialties Genitourinary Radiology Source Type: news